Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG, Investigators V. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal 2018, 206: 11-23. PMID: 30290289, DOI: 10.1016/j.ahj.2018.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood GlucoseBridged Bicyclo Compounds, HeterocyclicCardiovascular DiseasesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodEuropeFemaleFollow-Up StudiesGlycated HemoglobinHumansIncidenceMaleMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsSurvival RateTreatment OutcomeUnited StatesConceptsAtherosclerotic cardiovascular diseaseCardiovascular outcome trialsCV deathHeart failureComposite outcomeOutcome trialsMajor adverse CV eventsStage 3 kidney diseaseType 2 diabetes mellitusEfficacy of ertugliflozinVERTIS-CV trialAdverse CV eventsNonfatal myocardial infarctionDouble-blind placeboPeripheral arterial diseaseCoronary artery diseasePeripheral arterial systemCV eventsERTugliflozin effIcacyNonfatal strokeRenal safetyDiabetes durationBaseline characteristicsRenal deathSerum creatinine